Recent Acquisition Nimble Therapeutics was acquired by AbbVie for $200 million, indicating strong interest and potential for expanding its pipeline and projects through access to an established pharmaceutical powerhouse.

Innovative Platform The company leverages a cutting-edge peptide drug discovery platform combining parallel solid-phase synthesis, diverse chemical structures, and advanced machine learning, making it attractive for partners seeking innovative therapeutic solutions.

Therapeutic Focus Specializing in oral peptide therapeutics for autoimmune and immune-related diseases, Nimble offers strategic opportunities to develop and commercialize oral biologics within rapidly evolving immune health markets.

Funding & Revenue With a funding level of $10 million and annual revenues between $1 million and $10 million, Nimble presents opportunities for investment or partnership to accelerate pipeline advancement and scale-up activities.

Collaborative Relationships The company has established partnerships, such as with Genentech, across multiple therapeutic areas, indicating its openness to collaboration and potential for co-development or licensing deals.